You are here

Humira

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

5 Things You Need to Know From AbbVie's Q2 Earnings Results

5 Things You Need to Know From AbbVie's Q2 Earnings Results

Motley Fool

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

Endpoints

Samsung Bioepis

Flag link:

Merck's biosimilar to AbbVie's Humira wins FDA approval

Merck's biosimilar to AbbVie's Humira wins FDA approval

Reuters

Flag link:

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void

Fierce Pharma

Gilead Sciences

Flag link:

Why AbbVie's Stock Sank in the First Half of 2019

Why AbbVie's Stock Sank in the First Half of 2019

Motley Fool

Flag link:

5 reasons AbbVie bought Allergan, and why they may not be enough

5 reasons AbbVie bought Allergan, and why they may not be enough

Biopharma Dive

diversification

Flag link:

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

Stat

Flag link:

Meet the Top Ten Drugs of 2024 (Maybe)

Meet the Top Ten Drugs of 2024 (Maybe)

Drug Channels

Bristol-Myers Squibb

Flag link:

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Pharmaforum

psoriatic arthritis

Flag link:

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar

Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar

Fierce Pharma

CinnaGen Pharmaceuticals

Flag link:

Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose

Fierce Pharma

rheumatoid arthritis

Flag link:

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.

Marketwatch

Boehringer Ingelheim

Flag link:

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline

Marketwatch

Flag link:

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun

Fierce Pharma

Flag link:

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

Motley Fool

Flag link:

AbbVie successor to Humira in psoriasis gains FDA approval

AbbVie successor to Humira in psoriasis gains FDA approval

BioCentury

Flag link:

AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

Endpoints

Richard Gonzalez

Flag link:

Pages